Shankar Siva: Thank you, patients, families, and investigators, for contributing to the SEISMIC trial out now in The Lancet Respiratory Medicine
Quoting Shankar Siva, Radiation Oncologist at the Peter MacCallum Cancer Centre, on X/Twitter:
“Thank you, patients, families, and investigators, for contributing to the SEISMIC trial out now in The Lancet Respiratory Medicine led by Daniel Steinfort, this international multicentre recruited n=155 trial from Australia, Canada, USA and Netherlands.
EBUS biopsy is usually only single station to confirm diagnosis. With clinical N2 disease, radio-oncologists rely largely on PET avidity to define radio therapy fields. SEISMIC investigated systematic EBUS nodal staging in patients with locally advanced lung cancer undergoing radiotherapy.
n=155, in 37% PET/EBUS was discordant – 12% increase disease, 25% decrease disease extent. When upstaged with EBUS, missed lymph nodes get only ~10% of prescribed dose. We suggest use of systematic EBUS routinely before radiotherapy.
Some rapid, more easily digestible graphics of our paper and key outcomes below! Thank you everyone and interested in thoughts!!!”
Source: Shankar Siva/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023